OWL Blue Owl Capital Inc

Dividend
8.79%
Previous close
$10.30
Est. 12 months change
+45.32%
Projected Price
$15.02

Profitability Metrics

Return on Equity (ROE)
3.85%
Return on Assets (ROA)
0.70%
Return on Invested Capital (ROIC)
3.49%
Weighted Average Cost of Capital (WACC)
9.15%
ROIC - WACC
-5.66%
Updated : 2026-08-01 10:44 ET

Valuation Metrics

P/E Ratio
86.97
Forward P/E
11.45
PEG Ratio
1.03
Debt Current Ratio
2.10

Growth & Cash Flow

Gross Margin
55.41%
Operating Margin
21.34%
FCF Margin
43.63%
TTM Revenue Growth
7.10%
Projected 12M EPS Growth
659.81%

Price Change

Price % from 50 SMA
-22.23%
Price % from 200 SMA
-45.45%
6 Months
-46.60%
1 Year
-59.50%
2 Years
-53.70%
Click here to see the list of ETFs containing OWL as a top holding :Blue Owl Capital Inc ETFs

Analysis

Company Overview

Blue Owl Capital is an alternative asset manager specializing in direct lending, GP stakes, and net lease real estate for institutional investors. Sector: Financials.

Overview

Blue Owl Capital Inc (OWL) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Profitability & Capital Efficiency

On the question of capital productivity, ROIC is 3.49%, WACC is 9.15%, and the economic spread is -5.66%. On balance, the spread between returns and funding costs is negative — a dynamic that pressures intrinsic value unless operating performance improves. Supporting metrics show ROE at 3.85% and ROA at 0.70%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that likely needs operating improvement before returns quality can be considered durable.

Valuation

On a multiple basis, the company trades at trailing P/E of 86.97, forward P/E of 11.45, PEG of 1.03. The trailing-to-forward compression is notable, pointing to an earnings growth narrative that, if delivered, would make current valuations more defensible. The PEG reading here is low enough to suggest investors are not being asked to overpay for the growth embedded in analyst estimates. The company carries an aggregate current ratio of 2.10, consistent with adequate near-term liquidity management. The valuation setup is broadly consistent with a market that is pricing growth without being reckless about it — a balanced but not cautious stance.

Margins & Cash Generation

The margin stack reads as follows: gross margin sits at 55.41%, operating margin at 21.34%, and free cash flow margin at 43.63%. The gross margin reading points to the company with solid but not outsized pricing power relative to direct costs. The company's operating margins are solid, pointing to overhead management that appears to be a relative strength. The company's FCF margin is a standout — reflecting businesses where accounting profits translate cleanly into real cash generation. Viewed together, these readings indicate a company that converts revenue into both earnings and cash with discipline.

Growth & Forward Outlook

The forward view combines two signals: the estimated 12-month price change of 45.78%, where the forward target set implies considerable headroom versus current levels, while TTM revenue growth of 7.10% suggesting the company is growing revenues at a measured, sustainable pace. The projected 12-month EPS growth rate of 659.8% is a standout component of the forward case — meaningful earnings expansion at this scale typically warrants attention from growth-oriented investors. One metric reflects operational reality, the other market expectation — both are useful inputs, but neither should be read in isolation. The interaction between revenue execution and analyst repricing will ultimately determine how closely realized returns track current expectations. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Conclusion

Buy

The overall evidence base is constructive, with more signals pointing up than down and no obvious structural impairment to the forward case.

The analysis above draws from quantitative data only and does not constitute personalized financial advice. Investors should conduct independent research and consider professional guidance before acting on any information presented here.